| pubmed-article:1451644 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1451644 | lifeskim:mentions | umls-concept:C0004623 | lld:lifeskim |
| pubmed-article:1451644 | lifeskim:mentions | umls-concept:C1516213 | lld:lifeskim |
| pubmed-article:1451644 | lifeskim:mentions | umls-concept:C0028365 | lld:lifeskim |
| pubmed-article:1451644 | lifeskim:mentions | umls-concept:C0030771 | lld:lifeskim |
| pubmed-article:1451644 | lifeskim:mentions | umls-concept:C0199176 | lld:lifeskim |
| pubmed-article:1451644 | lifeskim:mentions | umls-concept:C1707455 | lld:lifeskim |
| pubmed-article:1451644 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:1451644 | pubmed:dateCreated | 1993-1-4 | lld:pubmed |
| pubmed-article:1451644 | pubmed:abstractText | In this study the efficacy of norfloxacin and pefloxacin for the antibacterial prophylaxis of granulocytopenia was compared in cancer patients following cytostatic treatment. A total of 136 patients was randomly selected to receive either norfloxacin or pefloxacin. Nineteen patients remained afebrile in the norfloxacin group compared with thirty one in the pefloxacin group (p = 0.045). Twenty four microbiologically documented infections (twelve with and twelve without bacteraemia) occurred in sixty seven patients taking norfloxacin, and twelve in sixty nine patients taking pefloxacin (five with and seven without bacteraemia) (p = 0.015). Only one infection caused by Gram-negative bacilli was observed in the pefloxacin group compared with seven in the norfloxacin group (p = 0.019). In conclusion, both microbiological and clinical results showed pefloxacin to be a better antibacterial agent than norfloxacin for these patients. | lld:pubmed |
| pubmed-article:1451644 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1451644 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1451644 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1451644 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1451644 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1451644 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1451644 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1451644 | pubmed:issn | 0378-6501 | lld:pubmed |
| pubmed-article:1451644 | pubmed:author | pubmed-author:IaconeAA | lld:pubmed |
| pubmed-article:1451644 | pubmed:author | pubmed-author:FioritoniGG | lld:pubmed |
| pubmed-article:1451644 | pubmed:author | pubmed-author:BettsEE | lld:pubmed |
| pubmed-article:1451644 | pubmed:author | pubmed-author:D'AntonioDD | lld:pubmed |
| pubmed-article:1451644 | pubmed:author | pubmed-author:RecchiaAA | lld:pubmed |
| pubmed-article:1451644 | pubmed:author | pubmed-author:Dell'IsolaMM | lld:pubmed |
| pubmed-article:1451644 | pubmed:author | pubmed-author:QuagliettaA... | lld:pubmed |
| pubmed-article:1451644 | pubmed:author | pubmed-author:PiergalliniAA | lld:pubmed |
| pubmed-article:1451644 | pubmed:author | pubmed-author:AccorsiPP | lld:pubmed |
| pubmed-article:1451644 | pubmed:author | pubmed-author:PantaloneVV | lld:pubmed |
| pubmed-article:1451644 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1451644 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:1451644 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1451644 | pubmed:authorsComplete | N | lld:pubmed |
| pubmed-article:1451644 | pubmed:pagination | 141-6 | lld:pubmed |
| pubmed-article:1451644 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:meshHeading | pubmed-meshheading:1451644-... | lld:pubmed |
| pubmed-article:1451644 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1451644 | pubmed:articleTitle | Comparison of norfloxacin and pefloxacin in the prophylaxis of bacterial infection in neutropenic cancer patients. | lld:pubmed |
| pubmed-article:1451644 | pubmed:affiliation | Department of Haematology, University of Chieti G. D'Annunzio, Italy. | lld:pubmed |
| pubmed-article:1451644 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1451644 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:1451644 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:1451644 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
